N2OFF, Inc. - Common Stock NITO 深 沪
等待开盘 11-06 09:30:00 美东时间
3.13
-0.020
-0.63%
华盛通- 最 高3.45
- 今 开3.16
- 成交量 2.65万股
- 最 低 3.11
- 昨 收 3.15
- 总市值 839.62万
- 52周最高 122.15
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 3.11
- 委 比 33.33%
- 总股本 268.25万
- 历史最高 2695.00
- 量 比 0.42
- 振 幅 10.79%
- 历史最低 3.11
- 每 手 1
- 风险率 12.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
N2OFF Inc. announces the completion of its merger with MitoCareX Bio Ltd, a biotech company focused on developing novel cancer therapies targeting mitochondrial SLC25 proteins. The transaction, valued at $700,000, makes MitoCareX a wholly-owned subsidiary of N2OFF, with the sellers receiving 40% of N2OFF’s fully diluted capital stock. N2OFF plans to support MitoCareX’s operations for the first two years. MitoCareX’s proprietary MITOLINE™ algorith...
10-30 13:25
N2OFF Finalizes Acquisition of MitoCareX Bio Ltd.
N2OFF ( ($NITO) ) has issued an announcement. On October 20, 2025, N2OFF comple...
10-24 04:40
N2OFF Closes Merger With MitoCareX Bio, Expanding Into Cancer Drug Discovery Targeting The Mitochondrial SLC25 Protein Family
N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today the closing of the merger with MitoCareX Bio
10-23 20:26
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
SciSparc Ltd. announce the sale of its subsidiary MitoCareX Bio Ltd. to N2OFF, Inc. MitoCareX focuses on developing novel cancer therapies targeting mitochondrial SLC25 proteins, utilizing its proprietary MITOLINE™ algorithm. The sale includes transferring 6,622 shares for $700,000 and exchanging remaining shares for 40% of N2OFF's common stock. SciSparc and other sellers will receive milestone-based payments up to 25% of N2OFF's common stock and...
10-23 20:03
N2OFF Regains Nasdaq Compliance with Bid Price
The latest update is out from N2OFF ( ($NITO) ). On October 8, 2025, N2OFF anno...
10-08 21:29
N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement
<p>Nasdaq-listed company N2OFF Inc. has regained compliance with the minimum bid price requirement after its ADS closing bid prices reached $1.00 or higher for 10 consecutive business days. The company had previously fallen below the $1.00 threshold for over 30 days. Formed on the RTB business model, N2OFF focuses on solar energy assets in the EU and holds a 98% stake in Save Foods Ltd., an Israeli company specializing in post-harvest treatments....
10-08 13:00
Market-Moving News for September 26th
NITO: -17% | NITO stock has given up its prior gain. N2OFF shares were trading higher after stockholders approved the acquisition of MitoCareX Bio. MRM: 468% | MEDIROM Healthcare Technologies Shares Move
09-26 19:19
N2OFF Stockholders Approve Acquisition of MitoCareX
An announcement from N2OFF ( ($NITO) ) is now available. On September 25, 2025,...
09-26 05:00
N2OFF shares are trading higher after stockholders approved the acquisition of MitoCareX Bio.
N2OFF shares are trading higher after stockholders approved the acquisition of ...
09-26 04:24
N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
N2OFF, a cleantech company, announced the approval of its stockholders for the acquisition of MitoCareX Bio Ltd, a biotech firm focused on cancer drug discovery targeting mitochondrial SLC25 proteins. The acquisition involves purchasing 6,622 shares from SciSparc Ltd for $700,000 and exchanging shares for 40% of N2OFF's capital stock. The sellers will also receive 30% of N2OFF's financing proceeds (capped at $1.6 million) over five years, plus mi...
09-25 20:01
